[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644052":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":11,"responsibleParty":28,"collaborators":11,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":11,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":11,"enrollmentInfo":39,"targetDuration":11,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":11,"overallStatus":48,"whyStopped":11,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":11},{"fullName":5,"class":6},"BrightPath Biotherapeutics Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"BP2202","EXPERIMENTAL",null,[13],"Biological: BP2202",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Intravenous infusion",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"BP2202 Study team","CONTACT","+81358407679","bp2202-001@brightpathbio.com",{"name":26,"role":22,"phone":11,"phoneExt":11,"email":27},"Director","zhang_l@brightpathbio.com",{"type":29,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100644052","a-phase-i-open-label-multicenter-study-to-evaluate-the-safety-and-tolerability-of-bp2202-in-patients-with-relapsedrefractory-multiple-myeloma-100644052",false,"NCT07667868","A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed\u002FRefractory Multiple Myeloma","A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Diagnosis of Multiple Myeloma with relapsed or refractory disease.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1\n* Adequate organ function.\n* Have measurable disease\n\nExclusion Criteria:\n\n* Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.\n* Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.","ALL","18 Years",{"count":40,"type":41},18,"ESTIMATED","INTERVENTIONAL",[44],"PHASE1","The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed\u002FRefractory Multiple Myeloma.",[47],"Relapsed\u002FRefractory Multiple Myeloma (RRMM)","NOT_YET_RECRUITING","2026-08-19",{"date":51,"type":52},"2026-08-21","ACTUAL",{"date":54,"type":41},"2026-10-01",{"date":56,"type":41},"2028-12-31",{"name":5,"class":6}]